RBOTOTCOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Vicarious Surgical Inc.
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Apr 30, 2026
$0.02+0.00 (+11.11%)
Close on Oct 19, 2026
- Market cap
- $134.10K
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 54.4% | -177.5% | |
| Return on assets | – | – | -115.0% | |
| Current ratio | – | 21.04 | 2.97 | |
| Interest coverage | – | -4328.3× | – | |
| Diluted shares | – | 3M | 6M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Vicarious Surgical generated $251.85M from operations and spent $8.62M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$251.85M
Used
$8.62M
Capital expenditure$8.62M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$50.18M
- Cash generatingOperating cash flow above zero-$45.08M
- Return on assets improvedROA up on the prior year-52.7% → -74.1%
- Earnings backed by cashOperating cash flow above net income-$45.08M vs -$50.18M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose6.74 → 2.97
- No dilutionShare count did not rise6M → 6M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –